Table 3.

Adverse events reported in ZISPAST trial

	Ziclague®	Placebo	p-value•
	N = 52	N = 52
Adverse events •	18 (35.3%)	22 (43.1%)	0.55
Blood pressure reduction	5 (9.8%)	4 (7.8%)	1.00
Somnolence	7 (13.7%)	8 (15.7%)	1.00
Weakness	1 (2.0%)	6 (11.8%)	0.13
Worsening gait	4 (7.8%)	4 (7.8%)	0.72
Worsening falls	1 (2.0%)	1 (2.0%)	0.48
Pain	2 (3.9%)	2 (3.9%)	0.62
Local allergy	2 (3.9%)	0 (0%)	0.48
Others	5 (9.8%)	6 (11.8%)	1.00

Number of patients who experienced adverse events (%). Considered on patients who completed at least two visits of the clinical trial (N = 52)